Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma

By  

Letters in Drug Design & Discovery, Vol. 1, Iss. 2, 2004-04 ,pp. : 135-136

Bentham Science Publishers

Access to resources Recommend Favorite

The US FDA has granted priority review for bortezomib [Velcade] for the treatment of patients with newly diagnosed multiple myeloma (MM).

By  

Inpharma, Vol. 1, Iss. 1624, 2008-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients

By van de Donk Niels WCJ   Lokhorst Henk M  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 12, 2013-08 ,pp. : 1569-1573

Informa Healthcare

Access to resources Recommend Favorite

Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma

By Jo Jae-Cheol   Kang Byung   Sym Sun   Lee Sung   Jang Geundoo   Kim Shin   Lee Dae   Kim Sang-We   Lee Jung   Suh Cheolwon  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 175-181

Springer Publishing Company

Access to resources Recommend Favorite

Bortezomib–Dexamethasone or Vincristine–Doxorubicin–Dexamethasone as Induction Therapy Followed by Thalidomide as Maintenance Therapy in Untreated Multiple Myeloma Patients

By Chen RA   Tu Y   Cao Y   Liu L   Liang Y  

The Journal of International Medical Research, Vol. 39, Iss. 5, 2011-09 ,pp. : 1975-1984

Field House Publishing

Access to resources Recommend Favorite